Q2 Results: Standalone Net Profit Doubles, Subsidiary Flagged

Going ConcernEmphasis Of MatterPat Growth 25pctExceptional ItemResults View source PDF Explain this filing

VENUSREM · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+14.3%Reaction day

₹465.45

prior close

₹548.00

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-0.3%+14.6% vs market

Pharmaceuticals peers, median of 157sector-0.2%+14.5% vs sector

On the reaction day the stock moved 14.6 pts more than Nifty Microcap 250 and 14.5 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-2.0

10m

-1.8

15m

-3.0

30m

-1.1

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+14.3-0.3+14.6-0.2+14.5

Next day

+15.2+0.7+14.5+0.5+14.7

+21.0+0.6+20.4+0.6+20.4

+22.0+0.5+21.5+0.3+21.7

+19.2+1.1+18.2+0.2+19.0

+18.4+0.3+18.1-0.6+19.0

+48.9-0.2+49.1-1.1+50.0

15d

+64.0-2.2+66.2-2.1+66.1

+79.4-4.9+84.3-3.2+82.6

+53.6-7.5+61.1-5.9+59.5

+62.9-4.8+67.6-6.4+69.3

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 157Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Venus Remedies posted strong Q2 FY26 standalone results. Revenue rose 13.5 percent YoY to about INR 192.65 Cr; net profit jumped 107 percent to INR 19.24 Cr. H1 revenue grew nearly 20 percent to INR 329.78 Cr with PAT up about 126 percent at INR 30.95 Cr. Operating cash flow nearly tripled to INR 79.78 Cr. However, auditor flagged material uncertainty over German subsidiary Venus Pharma GmbH (net worth eroded by INR 132 lakh) and stuck share application money of about INR 2,860 lakh.

Likely market impact

Strong profit growth is positive, but the going-concern flag on the German subsidiary and large stuck investment are real risks investors should watch closely.